Skip to main content


7 result(s) for 'author#Lukas C Heukamp' within BMC

Page 1 of 1

Sort by: Relevance | Date

  1. Hamartin (TSC1) and tuberin (TSC2), encoded by the tuberous sclerosis complex (TSC) genes, form a tumor-suppressor heterodimer which is implicated in PI3K-Akt signaling and acts as a functional inhibitor of the m...

    Authors: Angela Fuchs, Katharina König, Lukas C Heukamp, Jana Fassunke, Jutta Kirfel, Sebastian Huss, Albert J Becker, Reinhard Büttner and Michael Majores
    Citation: Diagnostic Pathology 2014 9:48
  2. Medulloblastoma is a leading cause of childhood cancer-related deaths. Current aggressive treatments frequently lead to cognitive and neurological disabilities in survivors. Novel targeted therapies are requir...

    Authors: Kristian W Pajtler, Christina Weingarten, Theresa Thor, Annette Künkele, Lukas C Heukamp, Reinhard Büttner, Takayoshi Suzuki, Naoki Miyata, Michael Grotzer, Anja Rieb, Annika Sprüssel, Angelika Eggert, Alexander Schramm and Johannes H Schulte
    Citation: Acta Neuropathologica Communications 2013 1:19
  3. Global histone modifications have been implicated in the progression of various tumour entities. Our study was designed to assess global methylation levels of histone 4 lysine 20 (H4K20me1-3) at different stag...

    Authors: Turang E Behbahani, Philip Kahl, Johannes von der Gathen, Lukas C Heukamp, Claudia Baumann, Ines Gütgemann, Bernhard Walter, Ferdinand Hofstädter, Patrick J Bastian, Alexander von Ruecker, Stefan C Müller, Sebastian Rogenhofer and Jörg Ellinger
    Citation: BMC Urology 2012 12:5
  4. High-risk neuroblastoma with N-Myc amplification remains a therapeutic challenge in paediatric oncology. Antagonism of pro-death Bcl-2 homology (BH) proteins to pro-survival BH members such as Mcl-1 and Bcl-2 ...

    Authors: Stefanie Klenke, Neval Akdeli, Patrick Stelmach, Lukas Heukamp, Johannes H. Schulte and Hagen S. Bachmann
    Citation: BMC Cancer 2019 19:243
  5. Lung cancer is one of the most common malignant neoplasms worldwide and has a high mortality rate. To enable individualized therapy regimens, a better understanding of the molecular tumor biology has still to ...

    Authors: Michael Majores, Anne Schindler, Angela Fuchs, Johannes Stein, Lukas Heukamp, Peter Altevogt and Glen Kristiansen
    Citation: BMC Clinical Pathology 2015 15:19
  6. Over the past years, EGFR tyrosine kinase inhibitors (TKI) revolutionized treatment response. 1st-generation (reversible) EGFR TKI and later the 2nd –generation irreversible EGFR TKI Afatinib were aimed to imp...

    Authors: Svenja Wagener-Ryczek, Carina Heydt, Juliane Süptitz, Sebastian Michels, Markus Falk, Christina Alidousty, Jana Fassunke, Michaela Angelika Ihle, Markus Tiemann, Lukas Heukamp, Jürgen Wolf, Reinhard Büttner and Sabine Merkelbach-Bruse
    Citation: BMC Cancer 2020 20:408